3-(imidazolyl)-pyrazolo[3,4-b]pyridines

Details 3-(imidazolyl)-pyrazolo[3,4-b]pyridines 3-(imidazolyl)-pyrazolo[3,4-b]pyridines

2008-05-21

2009-12-08

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S362000

Reexamination Certificate

active

07629344

ABSTRACT:
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

REFERENCES:
patent: 4238497 (1980-12-01), Black et al.
patent: 4443466 (1984-04-01), Karjalainen et al.
patent: 4927942 (1990-05-01), Speranza et al.
patent: 7157464 (2007-01-01), Pennell et al.
patent: 7449576 (2008-11-01), Pennell et al.
patent: 2004/0082571 (2004-04-01), Pennell et al.
patent: 2004/0162282 (2004-08-01), Pennell et al.
patent: 2005/0234034 (2005-10-01), Pennell et al.
patent: 2005/0256130 (2005-11-01), Pennell et al.
patent: 2006/0074121 (2006-04-01), Chen et al.
patent: 2006/0106218 (2006-05-01), Pennell et al.
patent: 2007/0010523 (2007-01-01), Zhang et al.
patent: 2007/0010524 (2007-01-01), Zhang et al.
patent: 2008/0058341 (2008-03-01), Zhang et al.
patent: WO 03/105853 (2003-12-01), None
patent: WO 2005/056015 (2005-06-01), None
patent: WO 2005/084667 (2005-09-01), None
patent: WO 2007/027734 (2007-03-01), None
patent: WO 2007/027734 (2007-03-01), None
Melter et al. Current Opinion in Organ Transplantation, vol. 7, p. 77-84 (2002).
Gladue et al. Chemokine Biology, vol. II, p. 103-113 (2007).
Bendele, A. et al., “Animal Models of Arthritis: Relevance to Human Disease,”Toxicologic Pathology, 1999, vol. 27, No. 1, pp. 134-142.
Bendele, A. et al., “Efficacy of Sustained Blood Levels of Interleukin-1 Receptor Antagonist in Animal Models of Arthritis,”Arthritis&Rheumatism, Mar. 1999, vol. 42, No. 3, pp. 498-506.
Dairaghi, D.J. et al., “Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength,”The Journal of Biological Chemistry, Nov. 7, 1997, vol. 272, No. 45, pp. 28206-28209.
Dairaghi, D.J. et al., “HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8,”The Journal of Biological Chemistry, Jul. 30, 1999, vol. 274, No. 31, pp. 21569-21574.
Hesselgesser, J. et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor,”The Journal of Biological Chemistry, Jun. 19, 1998, vol. 273, No. 25, pp. 15687-15692.
International Search Report mailed on Aug. 6, 2008, for International Application No. PCT/US08/64374 filed on May 21, 2008, 2 pages.
Jones, J. et al., “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome,” Division of Gastroenterology, University Hospital, Nottingham, UK, 19 pages.
Liang, M. et al., “Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1,”The Journal of Biological Chemistry, Jun. 23, 2000, vol. 275, No. 25, pp. 19000-19008.
Liang, M. et al., “Species Selectivity of a small molecule antagonist for the CCR1 chemokine receptor,”European Journal of Pharmacology, 2000, vol. 389, pp. 41-49.
Ng, H.P. et al., “Discovery of Novel Non-Peptide CCR1 Receptor Antagonists,”Journal of Medicinal Chemistry, 1999, vol. 42, No. 22, pp. 4680-4694.
Palmer, A.M., “Pharmacotherapy for Alzheimer's disease: progress and prospects,”Trends in Pharmacological Sciences, Sep. 2002, vol. 23, No. 9, pp. 426-433.
Penfold, M.E.T. et al., “Cytomegalovirus encodes a potent α chemokine,”Proc. Natl. Acad. Scie. USA, Aug. 1999, vol. 96, pp. 9839-9844.
Podolin, P.L. et al. “A Potent and Selective Nonpeptide Anatagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit,”The Journal of Immunology, 2002, vol. 169, pp. 6435-6444.
Trentham, D.E. et al., “Autoimmunity to Type II Collagen: An Experimental Model of Arthritis,”The Journal of Experimental Medicine, 1977, vol. 146, pp. 857-868.

Affiliated with

Also associated with

Rating

3-(imidazolyl)-pyrazolo[3,4-b]pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-(imidazolyl)-pyrazolo[3,4-b]pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(imidazolyl)-pyrazolo[3,4-b]pyridines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4113373